ReviewBioMed research international2015
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Defining and modeling 'cure' in early-stage melanoma: perspectives from a systematic literature review.Frontiers in oncology · 2026Pooled it
- The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.British journal of cancer · 2026Article
- Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice.Breast (Edinburgh, Scotland) · 2026Observational
- Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada.Current oncology (Toronto, Ont.) · 2026Article
- Article
- Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.Cancer medicine · 2024Article
- Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.Journal of applied statistics · 2024Article
- Optimal Personalized Treatment Selection with Multivariate Outcome Measures in a Multiple Treatment Case.Communications in statistics: Simulation and computation · 2023Article
- Article
- Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.Statistics in medicine · 2022Article
- The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer.The patient · 2022Article
- Assessing potential cures: are there distinctive elements of value beyond health gain?Journal of comparative effectiveness research · 2021Article
- Patients' understanding of oncology clinical endpoints: A literature review.Patient education and counseling · 2020Review
- Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.Advances in therapy · 2019Article
- Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study.Advances in therapy · 2019Article
- Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.Journal of managed care & specialty pharmacy · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with certain cancers are treated with curative intent, but for others the results are less favorable and different therapeutic approaches are needed. Early data suggest that new therapies, which modulate immune responses to cancers, may have potential for long-term survival in a proportion of cases. Therefore, it is timely to consider whether metrics generally used to describe the medical value of therapies for patients with common solid tumors remain appropriate for therapies with curative potential. Literature reviews were conducted to define how various stakeholders describe cure in oncology and to identify the endpoints used in clinical trials for selected solid tumors. The results showed that "cure" is described using various terms that can be divided broadly into lack of disease progression, eradication of cancerous cells, and survival. The review of trial endpoints showed frequent use of median overall survival (OS) and progression- and response-related endpoints. Because these endpoints were mainly described in the context of chemotherapies that are not generally curative, they may not adequately capture outcomes of new therapeutic modalities with potential for long-term survival. More appropriate endpoints may include mean OS, cure fraction, and OS rate at landmark time points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.